Table 2.
In vitro activity of SMT19969 against isolates of Clostridium difficile according to grouping of ribotypes most frequently encountered in our study
| Ribotype (n) | MIC (μg/ml) |
||
|---|---|---|---|
| Range | MIC50 | MIC90 | |
| Ribotype 002 (8) | |||
| SMT19969 | 0.125–0.25 | 0.25 | |
| Fidaxomicin | 0.06–0.25 | 0.25 | |
| Vancomycin | 1–2 | 1 | |
| Metronidazole | 0.25–0.5 | 0.5 | |
| Ribotype 014 (8) | |||
| SMT19969 | 0.125–0.25 | 0.125 | |
| Fidaxomicin | 0.06–0.5 | 0.25 | |
| Vancomycin | 1–2 | 1 | |
| Metronidazole | 0.25–0.5 | 0.5 | |
| Ribotype 027 (11) | |||
| SMT19969 | 0.25–0.5 | 0.25 | 0.25 |
| Fidaxomicin | 0.5–1 | 0.5 | 0.5 |
| Vancomycin | 1–8 | 2 | 4 |
| Metronidazole | 2–8 | 2 | 8 |
| Ribotype 054 (4) | |||
| SMT19969 | 0.125–0.25 | 0.25 | |
| Fidaxomicin | 0.125 | 0.125 | |
| Vancomycin | 1–2 | 1 | |
| Metronidazole | 0.5 | 0.5 | |